According to WHO Global Hepatitis Report 2024, nearly 254 million individuals have hepatitis B. Credit: chemical industry/Shutterstock.com.

AusperBio has completed patient enrolment for the Phase III AUSHINE clinical trial evaluating AHB-137 for chronic hepatitis B (CHB).

The multicentre, randomised, double-blind study is assessing the safety and efficacy of AHB-137 injection in participants with HBeAg-negative CHB who are receiving nucleos(t)ide analogue therapy.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

CHB continues to present a significant public health challenge globally. According to the World Health Organization (WHO) Global Hepatitis Report 2024, there are nearly 254 million individuals living with hepatitis B virus (HBV) globally, with 1.2 million new infections each year.

AHB-137 is an unconjugated antisense oligonucleotide (ASO) developed using AusperBio’s Med-Oligo ASO platform, intended to achieve a functional cure of CHB.

The investigational therapy’s mechanism integrates immune reactivation, targeted HBsAg suppression at the transcriptional level, and inhibition of viral DNA replication.

It has completed a global Phase I trial and is currently being assessed in multiple Phase II studies alongside the ongoing Phase III trial in China.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The global development strategy for AHB-137 aims to deliver a treatment that could potentially offer a functional cure for HBV infection.

AusperBio co-founder and CEO Dr Guofeng Cheng said: “The successful enrolment of over 570 patients ahead of schedule marks a critical milestone in our mission to advance a functional cure for CHB.

“Full enrolment was achieved within five months of China CDE approval, reflecting the strong engagement and dedication of the investigators, patients, clinical teams who partnered with us in this programme.

“We are deeply grateful and remain firmly committed to advancing AHB-137 through a rigorous registrational pathway, guided by strong science and a clear focus on delivering a paradigm-shifting treatment for people living with CHB.”

In September 2025, AusperBio completed participant enrolment in two Phase II studies evaluating AHB-137 for the functional cure of CHB.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact